NCT03881306 is a Phase 1, PHASE2 clinical trial of D-TACE in Neuroendocrine Tumors, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT03881306?

NCT03881306 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT03881306?

Interventions in NCT03881306: D-TACE.

What condition does NCT03881306 study?

NCT03881306 studies Neuroendocrine Tumors, Neoplasm Metastasis, Liver.

Is NCT03881306 still recruiting?

NCT03881306 is currently status unknown. Last updated 20 August 2020.

Last reviewed 2020-08-20 · How we verify

NCT03881306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DEBOXA for Inoperable NET Liver Metastases

Status unknown Phase 1, PHASE2 Last updated 20 August 2020

What this trial tests

Phase 1, PHASE2 trial testing D-TACE in Neuroendocrine Tumors in 60 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2018
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

D-TACE — full drug profile →

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
Liver — all drugs for Liver →

Sponsor

Xiangya Hospital of Central South University

Who can join

Adults 18 to 75, any sex, with Neuroendocrine Tumors or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective clinical trial to study the safety and effectiveness of Transcatheter Artery Chemotherapy and Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin (DEBOXA) in treating patients who have inoperable neuroendocrine neoplasm (NEN) liver metastases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.
Dermine S, Palmieri LJ, Lavolé J, Barré A, et al · · 2019 · cited 7× · PMID 31703375 · DOI 10.3390/jcm8111907

Verify or expand the search:

Other trials of D-TACE

Trials testing the same drug.

NCT05738057 — Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cho · Phase 2 · unknown
NCT05582278 — HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC · Phase 2 · unknown

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03881306 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 20 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03881306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing